Drug Discovery Targeting the MAPK-ERK Pathway
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: closed (5 July 2023) | Viewed by 1716
Special Issue Editor
Special Issue Information
Dear Colleagues,
Drug discovery of targeting the mitogen-activated protein kinase (MAPK) pathway has been implicated in various diseases, including cancer treatment, neurological diseases, inflammatory disorders, etc. Members of the MAPK pathway are constituted by serine/threonine kinases that involve multiple cell responses, such as gene expression, cell growth, differentiation, development, and cell death. The MAPK pathway can be stimulated or attenuated by extracellular stimuli and/or intracellular signaling cross-talk effects. There is no doubt that ERK1 and ERK2 are major cell signals that promote many types of cancer growth. Many inhibitors in this pathway have been approved and clinically evaluated; however, the response rates and prognosis of patients are still very low. This Special Issue welcomes any manuscripts or reviews dedicated to the study of drug resistance, dosage use in targeted therapy and combination treatments to modulate this pathway.
Dr. Yung-Chia Chen
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- MAPK
- ERK
- JNK
- tyrosine kinase
- cancer
- cell growth
